Default object view. Click to create a custom template, Node ID: 132097, Object ID: 77814

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adap...

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

No relation

Yes

No relation

No

21/12/2015 2:16 pm

No